IMRT 2018

Final Remarks

• SBRT is currently widely accepted as the best alternative to surgery for inoperable early stage lung cancer • SBRT might be offered also to operable patients • IGRT-motion management are essential for prescribing high BED: IMRT is an option • Mature data with long-term follow up are needed to better understand the pattern of relapse across time • Predictive and prognostic factors are needed to possibly offer to higher risk patients adjuvant therapies (immuntherapy?)